

# Quantifying and modifying ultra-processed food intake in the management of functional dyspepsia

<b>Submission date</b> 15/05/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/05/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 01/07/2025	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Functional dyspepsia (FD) is a common digestive condition that causes discomfort in the upper part of the stomach, such as pain, bloating, and feeling overly full. These symptoms can make it hard for people to go about their normal routines. While medications are the main treatment for FD, they often only provide partial relief and may not work for everyone. Some foods have been linked to FD symptoms, but the idea of using special diets to treat FD hasn't been studied much, and current advice is inconsistent. Recently, there's been growing concern about the effects of ultra-processed foods (UPFs) on health, including digestive issues like FD. UPFs are foods heavily changed through industrial processing and often have added chemicals like preservatives, flavour enhancers, and artificial ingredients. In this study, we want to learn if people with FD tend to eat a lot of UPFs. This could help us understand if high UPF intake is common among people with FD.

### Who can participate?

Adults aged between 18 and 65 years with functional dyspepsia

### What does the study involve?

For those who eat a lot of UPFs, we'll test if switching to a minimally processed food (MPF) diet can help reduce symptoms. Along with diet changes, we'll support participants in building healthy habits that they can maintain long-term. Over 6 months, we'll track changes in symptoms, quality of life, and other health indicators. Our goal is to see if reducing UPF intake could be a new, effective treatment for people living with FD.

### What are the possible benefits and risks of participating?

We do not know whether people will benefit personally from taking part in this study, but the knowledge gained from this study will inform future research and treatments into FD. If patients proceed to phase 2 (the minimally processed food diet intervention), it is likely they will experience a benefit because they will be supported to improve their diet and be more physically active. This may have a benefit on both their digestive symptoms and general health. There are possible disadvantages and risks related to the study assessments, procedures, and

questionnaires that patients will have to undergo when taking part in the study. This can include minor discomfort from blood tests and discussing sensitive or upsetting. Overall, the study is low risk. We do not expect there to be any major risks or adverse events from taking part in the study.

Where is the study run from?

This research study is being organised by the Centre for Obesity Research at University College London (UCL). UCL is the sponsor for this study based in the United Kingdom. The sponsor is the organisation responsible for ensuring that the study is carried out correctly. Participants will be identified from patients be referred to University College London Hospital (UCLH) for the investigation of dyspepsia and subsequently diagnosed with functional dyspepsia based on the findings of 'negative' investigations.

When is the study starting and how long is it expected to run for?

March 2025 to October 2026

Who is funding the study?

This study is being funded as part of a doctoral research project at University College London. Additional funding has been sought but has not yet been confirmed. Any further information about the funding of the study will be provided once additional information has been received from the grant applications.

Who is the main contact?

Dr Benjamin Norton, [benjamin.norton@nhs.net](mailto:benjamin.norton@nhs.net)

## Contact information

### Type(s)

Principal Investigator

### Contact name

Prof Abigail Fisher

### ORCID ID

<https://orcid.org/0000-0001-9284-6780>

### Contact details

UCL Department of Behavioural Science and Health  
1-19 Torrington Place  
London  
United Kingdom  
WC1E 7HB  
+44 (0)20 7679 1722  
[abigail.fisher@ucl.ac.uk](mailto:abigail.fisher@ucl.ac.uk)

### Type(s)

Public, Scientific, Principal Investigator

### Contact name

Dr Benjamin Norton

**ORCID ID**

<https://orcid.org/0000-0003-2058-3162>

**Contact details**

Centre for Obesity Research  
Rayne Institute  
5 University Street  
London  
United Kingdom  
WC1E 6JF  
+44 (0)20 3549 5979  
[benjamin.norton@nhs.net](mailto:benjamin.norton@nhs.net)

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number**

348984

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

176078

**Study information****Scientific Title**

A prospective, pragmatic, pilot study to quantify the degree of ultra-processed food intake in patients with functional dyspepsia, and assess the impact of a minimally processed food diet as a treatment modality

**Acronym**

FD-ULTRA

**Study objectives**

It is hypothesised that adult patients referred to secondary care for investigation of dyspepsia, and subsequently diagnosed with functional dyspepsia based on the presence of negative investigations, will, on average, consume a high proportion of ultra-processed foods (UPFs) in their diet. Furthermore, among those diagnosed with functional dyspepsia who consume the highest proportion of UPF in their diet, as determined by contribution to their daily caloric intake (e.g.  $\geq 50\%$ ), a structured dieting programme consisting of behavioural support and an minimally processed food (MPF) diet would be beneficial in terms of improvements to symptoms and quality-of-life.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

Approved 18/03/2025, North West - Preston Research Ethics Committee (Barlow House, 4 Minshull Street, Manchester, M1 3DZ, United Kingdom; +44 (0)161 625 7818; nrescommittee.northwest-preston@nhs.net), ref: 25/NW/0055

**Study design**

Prospective pragmatic pilot study

**Primary study design**

Interventional

**Secondary study design**

Non randomised study

**Study setting(s)**

Hospital

**Study type(s)**

Quality of life, Treatment, Efficacy

**Participant information sheet**

Not available in web format

**Health condition(s) or problem(s) studied**

Functional dyspepsia

**Interventions**

The researchers are recruiting 126 patients as part of an observational study to look at the association between functional dyspepsia and ultra-processed food. Among these 126, 24 will be recruited to take part in the interventional proportion, which will be testing a minimally processed food diet and its impact on gastrointestinal symptoms.

Patients initially screened for the observational study (V1) complete a medical assessment and a series of questionnaires, then exit the study. Among those with the highest intake of ultraprocessed food based on the Intake24 dietary recall questionnaire ( $\geq 50\%$ ), they will be invited to take part in the intervention. This will be a minimally processed food diet, provided by researchers/dietitians/psychologists, which involves education, behavioural changes, recipe advice, leaflets and motivational interviewing at baseline and then 1-, 3-, and 6-months follow-up. These will be face-to-face. The sessions will be centred around ultra-processed food and will be tailored to the needs of the individual (e.g work schedule, dietary requirements, cooking skills, finances).

**Intervention Type**

Behavioural

**Primary outcome measure**

1. The proportion of ultra-processed food intake within the diet of individuals diagnosed with functional dyspepsia measured at screening using the Intake24 dietary recall questionnaire ( $\geq 3$  24-hour recalls over a 7-day period) that has been modified to account for ultra-processed food

intake.

2. Gastrointestinal symptom severity measured using the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) at baseline, 3 and 6 months

### **Secondary outcome measures**

Observational cohort:

1. Gastrointestinal symptoms measured using patient assessment of upper gastrointestinal symptoms (PAGI-SYM) and the Visceral Sensitivity Index (VSI) at baseline stratified by groups based on UPF consumption
2. Quality of life measured using the Patient Assessment of Upper Gastrointestinal Disorders–Quality of Life (PAGI-QOL) and EQ-5D-5L at baseline stratified by groups based on UPF consumption
3. Psychological health measured using the Patient Health Questionnaire (PHQ-9) and the Generalised Anxiety Disorder Questionnaire (GAD-7) at baseline stratified by groups based on UPF consumption
4. Eating behaviour and patterns measured using the Food Frequency Questionnaire (FFQ) at baseline stratified by groups based on UPF consumption
5. Biometrics measured using bioelectrical impedance analysis at baseline stratified by groups based on UPF consumption

Interventional cohort:

1. Gastrointestinal symptoms measured using PAGI-SYM, VSI at 1-, 3-, and 6-months follow-up
2. Quality of life measured using PAGI-QOL, EQ-5D-5L at 1-, 3-, and 6-months follow-up
3. Psychological health measured using PHQ-9, GAD-7 at 1-, 3-, and 6-months follow-up
4. Biometrics measured using bioelectrical impedance analysis at 1-, 3-, and 6-months follow-up
5. Eating behaviour and patterns measured using Intake24 at 1-, 3-, and 6-month follow-up

### **Overall study start date**

18/03/2025

### **Completion date**

01/10/2026

## **Eligibility**

### **Key inclusion criteria**

1. Adults aged  $\geq 18$  and  $< 65$  years old
2. Diagnosed with functional dyspepsia based on the Rome IV Clinical Diagnostic Criteria; bothersome epigastric pain or burning, early satiation, and/or postprandial fullness of greater than 8 weeks duration, and no evidence of structural disease (including at upper endoscopy) likely to explain the symptoms
3. Able to read and write in English
4. Willing and able to give written informed consent

Additional inclusion (interventional phase):

1. A habitual diet high in UPF, as defined by  $\geq 50\%$  of total energy intake from UPFs
2. Women of childbearing potential (WOCBP) should have a negative urine beta human chorionic gonadotrophin (hCG) pregnancy test within 28 days of diet initiation and agree to use one established method of contraception throughout the study duration

3. Medically safe to participate in a dietary intervention programme
4. Able to comply with the study protocol, including dietary recommendations, attending sessions and confirming adherence throughout dietary recall

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

64 Years

**Sex**

Both

**Target number of participants**

126

**Key exclusion criteria**

1. Confirmed helicobacter pylori infection based on stool antigen test, rapid urease test (CLO), and/or histopathological assessment
2. Coeliac disease or villous atrophy
3. A diagnosed eating disorder
4. Body mass index (BMI)  $<18.5$  or  $\geq 45$  kg/m<sup>2</sup>
5. Use of non-steroidal anti-inflammatory drugs or corticosteroids
6. Inflammatory bowel disease
7. Co-existent diagnosis of irritable bowel syndrome
8. Co-existent diagnosis of gastro-oesophageal reflux disease, functional heartburn or reflux hypersensitivity (bothersome retrosternal symptoms including discomfort, heartburn, regurgitation, and/or chest pain; intermittent symptoms not affecting quality of life are allowed)
9. Known structural disorder of the upper gastrointestinal tract (neoplasia, Barrett's oesophagus, hiatus hernia  $\geq 4$  cm, oesophagitis  $\geq$  grade B, pharyngeal pouch, oesophago-gastric varices, erosive gastritis, active peptic ulcer disease, previous oesophago-gastric surgery)
10. Severe psychiatric disorder that might interfere with study participation or adherence
11. Women who are pregnant or breastfeeding
12. History of alcohol or substance abuse
13. Use of artificial nutrition

**Additional exclusion (interventional phase):**

1. Contraindication for dietary intervention
2. Any diagnosed food allergy, or other allergies, which limit the ability to adhere to the intervention diet
3. Any major dietary restrictions which limit the ability to adhere to the dietary intervention
4. A suspected eating disorder based on the EDE-QS questionnaire
5. History of major cardiorespiratory co-morbidities (e.g. myocardial infarction, chronic heart failure exacerbation, stroke, TIA, or major event requiring hospitalisation within the last 6 months)

6. History of new or worsening signs or symptoms of coronary heart disease (CHD) within the last 3 months
7. Known case of symptomatic heart failure with reduced ejection fraction (NYHA Class II-IV) requiring pharmacologic therapy to control symptoms
8. Severe anaemia ( $\leq 80$  g/L)
9. Known case of severe peripheral vascular disease
10. History of moderate to severe chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) of  $< 30$  mL/min/1.73m<sup>2</sup> (estimated by Modification of Diet in Renal Disease (MDRD)), end-stage renal failure, or on dialysis
11. Symptomatic gallstones, symptomatic kidney stones, or acute cholecystitis
12. Clinically active systemic infection
13. Known history of chronic pancreatitis or a recent history of acute pancreatitis within the past year
14. History of active malignancy or partial remission from clinically significant malignancy within the past 5 years (except basal or squamous cell skin cancer, carcinoma in situ, those who received curative treatment and are in complete remission for 5 years, or if the subject is confirmed as cancer free)
15. Participation in another clinical intervention trial
16. Use of a neuromodulating agent (e.g. tricyclic anti-depressants, selective serotonin reuptake inhibitors, anti-psychotics, serotonin norepinephrine reuptake inhibitors, mirtazapine, etc)
17. Use of an anti-acid therapy (e.g. PPI, H<sub>2</sub>A), which has been changed within the last four weeks and cannot remain stable for the duration of the trial.
18. Use of a medication that can affect the motility of the stomach (e.g. domperidone, metoclopramide, glucagon-like 1 peptide receptor agonist, prucalopride), which cannot be stopped for the duration of the dietary intervention, including at least 14 days before the baseline visit.
19. Poorly controlled diabetes as evidenced by  $>2$  oral anti-diabetic agents, use of an injectable anti-diabetic medication, diabetes  $>8$  years duration, or a glycated haemoglobin  $\geq 53$  mmol/mol.
20. Recovered from severe COVID-19 infection (requiring hospitalization) but with persistent long COVID-19 symptoms (i.e., the individual has not recovered for several weeks or months since the start of symptoms that were suggestive of COVID-19, irrespective of whether the individual is tested or not)
21. Any other mental or physical condition which, in the opinion of the investigator, makes the subject a poor candidate for clinical-trial participation

**Date of first enrolment**

01/08/2025

**Date of final enrolment**

01/07/2026

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

University College London Hospitals NHS Foundation Trust  
250 Euston Road  
London  
United Kingdom  
NW1 2PG

**Study participating centre**

University College London Centre for Obesity Research  
Rayne Institute  
5 University Street  
London  
United Kingdom  
WC1E 6JF

## **Sponsor information**

**Organisation**

University College London

**Sponsor details**

Gower Street  
London  
England  
United Kingdom  
+44 (0)171 380 7784  
WC1E 6BT  
study@ucl.ac.uk

**Sponsor type**

University/education

**Website**

<https://www.ucl.ac.uk/>

**ROR**

<https://ror.org/02jx3x895>

## **Funder(s)**

**Funder type**

Other



**Funder Name**

Investigator initiated and funded

## **Results and Publications**

**Publication and dissemination plan**

Upon completion of the trial and data analysis, a Final Trial Report will be prepared, and results will be disseminated. UCL, as Sponsor, will have ownership of the data that will be shared with the funders. The PI and trial investigators will have rights to publish data originating from the trial. Trial results will be disseminated, in anonymised form, via conference presentations, abstracts, scientific journals, medical meetings, patient support group meetings, and/or trust /charity websites.

**Intention to publish date**

01/12/2026

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are not expected to be made available due to it being a student related project

**IPD sharing plan summary**

Not expected to be made available